These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 7847102

  • 21. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
    Gianola D, Pedroncelli A, Montini M, Tengattini F, Pagani MD, Cortesi L, Cappi MP, Gherardi F, Lancranjan I, Pagani G.
    Gynecol Endocrinol; 1991 Sep; 5(3):213-6. PubMed ID: 1776507
    [Abstract] [Full Text] [Related]

  • 22. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
    van't Verlaat JW, Croughs RJ, Brownell J.
    Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
    [Abstract] [Full Text] [Related]

  • 23. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
    Newman CB, Hurley AM, Kleinberg DL.
    Clin Endocrinol (Oxf); 1989 Oct; 31(4):391-400. PubMed ID: 2576397
    [Abstract] [Full Text] [Related]

  • 24. Quinagolide in the management of prolactinoma.
    Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M, Gagel RF.
    Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
    [Abstract] [Full Text] [Related]

  • 25. Long-term treatment of macroprolactinomas with CV 205-502.
    Kvistborg A, Halse J, Bakke S, Bjøro T, Hansen E, Djøseland O, Brownell J, Jervell J.
    Acta Endocrinol (Copenh); 1993 Apr; 128(4):301-7. PubMed ID: 8098891
    [Abstract] [Full Text] [Related]

  • 26. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

  • 27. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J.
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [Abstract] [Full Text] [Related]

  • 28. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I.
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
    [Abstract] [Full Text] [Related]

  • 29. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
    Ciccarelli E, Ghigo E, Mazza E, Andreis M, Massara F, Lancranjan I, Camanni F.
    J Endocrinol Invest; 1987 Apr; 10(2):179-82. PubMed ID: 3584856
    [Abstract] [Full Text] [Related]

  • 30. Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics.
    Espinós JJ, Rodríguez-Espinosa J, Webb SM, Calaf-Alsina J.
    Fertil Steril; 1994 Nov; 62(5):926-31. PubMed ID: 7926136
    [Abstract] [Full Text] [Related]

  • 31. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
    Homburg R, West C, Brownell J, Jacobs HS.
    Clin Endocrinol (Oxf); 1990 May; 32(5):565-71. PubMed ID: 1973085
    [Abstract] [Full Text] [Related]

  • 32. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E, Crabbé J, Donckier J.
    Horm Res; 1998 May; 49(5):250-3. PubMed ID: 9568811
    [Abstract] [Full Text] [Related]

  • 33. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [Abstract] [Full Text] [Related]

  • 34. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.
    Razzaq R, O'Halloran DJ, Beardwell CG, Shalet SM.
    Horm Res; 1993 Feb; 39(5-6):218-22. PubMed ID: 7906243
    [Abstract] [Full Text] [Related]

  • 35. Usefulness of CV 205-502 in a case of allergy to ergot-derived drugs.
    Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Caruso E, Lombardi G.
    Horm Res; 1992 Feb; 38(3-4):190-2. PubMed ID: 1306852
    [Abstract] [Full Text] [Related]

  • 36. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [Abstract] [Full Text] [Related]

  • 37. [The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation].
    Kreft B, Peters A, Kerner W.
    Dtsch Med Wochenschr; 1996 Jul 05; 121(27):865-8. PubMed ID: 8681742
    [Abstract] [Full Text] [Related]

  • 38. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G.
    J Clin Endocrinol Metab; 1998 Aug 05; 83(8):2777-80. PubMed ID: 9709946
    [Abstract] [Full Text] [Related]

  • 39. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P.
    Eur J Endocrinol; 1996 Oct 05; 135(4):413-20. PubMed ID: 8921822
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.